MARKET

BEAM

BEAM

BEAM THERAPEUTICS INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

90.37
+1.76
+1.99%
Closed 18:17 07/29 EDT
OPEN
89.63
PREV CLOSE
88.61
HIGH
92.96
LOW
88.11
VOLUME
481.29K
TURNOVER
--
52 WEEK HIGH
138.52
52 WEEK LOW
18.76
MARKET CAP
5.66B
P/E (TTM)
-14.0897
1D
5D
1M
3M
1Y
5Y
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. If you want to skip our detailed analysis of Simons’ history, investment philosophy, and hedge fund performance, go directly to the 5 ...
Insider Monkey · 1d ago
Were Hedge Funds Right About Beam Therapeutics Inc. (BEAM)?
At Insider Monkey, we pore over the filings of nearly 866 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on ...
Insider Monkey · 2d ago
Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next?
For most of the past year, just a handful of companies carried the biotech sector, thanks to their quick responses to the COVID-19 pandemic.
Benzinga · 07/21 15:49
Thinking about buying stock in Covanta, Vertex Energy, OncoSec Medical, Energous Corp, or Beam Therapeutics?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CVA, VTNR, ONCS, WATT, and BEAM.
PR Newswire - PRF · 07/14 14:30
WHO Issues Framework For Governance For Gene Editing Technologies
Benzinga · 07/12 19:12
WHO urges fair access to gene-editing technologies
Andy/iStock via Getty Images An expert panel from the World Health Organization ((WHO)) has called for a generous distribution of gene editing technologies to enable the poorer countries to benefit
Seekingalpha · 07/12 15:51
A Comprehensive Guide to Genomic ETFs
Zacks.com · 07/09 20:04
Beam Therapeutics Inc (BEAM) CEO John M. Evans Sold $2.7 million of Shares
GuruFocus News · 07/09 10:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BEAM. Analyze the recent business situations of BEAM THERAPEUTICS INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BEAM stock price target is 109.83 with a high estimate of 150.00 and a low estimate of 62.00.
EPS
Institutional Holdings
Institutions: 212
Institutional Holdings: 44.27M
% Owned: 70.74%
Shares Outstanding: 62.58M
TypeInstitutionsShares
Increased
66
8.99M
New
63
2.78M
Decreased
40
5.28M
Sold Out
15
1.59M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
President/Chief Scientific Officer
Giuseppe Ciaramella
Chief Executive Officer/Director
John Evans
Chief Financial Officer/Treasurer
Terry-Ann Burrell
Independent Director
Kristina Burow
Independent Director
Graham Cooper
Independent Director
Mark Fishman
Independent Director
Carole Ho
Independent Director
Kathleen Walsh
No Data
About BEAM
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines based on its base editing technology, to providing life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). Its programs are organized by delivery modality into three distinct pipelines: electroporation for delivery to blood cells and immune cells; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future; and adeno-associated viral vectors (AAV), for viral delivery to the eye and central nervous system (CNS). The Company has three development candidates, such as BEAM-101, BEAM-102 and BEAM-201 in which two candidates targeting hemoglobinopathies and one candidate in T-cell therapy program.

Webull offers kinds of Beam Therapeutics Inc stock information, including NASDAQ:BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.